The effects of trifluoromethylated derivatives on prostaglandin E2 and thromboxane A2 production in human leukemic U937 macrophages.

BACKGROUND Convenient approach to modulation of the inflammation is influence on production of inflammatory mediators - eicosanoids, generated in arachidonic acid (AA) metabolism. Common therapeutic activity of non-steroidal anti-inflammatory drugs (NSAID), such as aspirin, includes inhibition of two crucial enzymes of AA metabolism - cyclooxygenase-1 and -2 (COX-1/2), with certain risk for gastrointestinal and renal intolerance. Ever since enrolment of COX-2, particularly overabundance of its main products prostaglandin E2 (PGE2) and thromboxane A2 (TXA2) in numerous pathological processes was recognized, it became significant therapeutic target. OBJECTIVE The aim of this study was to examine effects of synthesized organo-fluorine compounds on PGE2 and TXA2 production in inflammation process. METHODS Trifluoromethyl compounds were synthesized from N-benzyl trifluoromethyl aldimine, commercially available 2-methyl or 2-phenyl -bromo esters (β-lactams trans-1 and trans-2 and trifluoromethyl β-amino ester, respectively) and methyl 2-isocyanoacetate (2-imidazoline trans-4). The reactions proceeded with high geometric selectivity, furnishing the desired products in good yields. The influence of newly synthesized compounds on PGE2 and TXA2 production in human leukemic U937 macrophages on both enzyme activity and gene expression levels was observed. RESULTS Among tested trifluoromethyl compounds, methyl trans-1-benzyl-5-(trifluoromethyl)-4,5-dihydro-1H-imidazole-4-carboxylate (trans-4) can be distinguished as the most powerful anti-inflammatory agent, probably due to its trifluoromethyl-imidazoline moiety. CONCLUSIONS Some further structural modification of tested compounds and particularly synthesis of different trifluoromethyl imidazolines could contribute to development of new COX-2 inhibitors and potent anti-inflammatory agents.

[1]  S. Fioravanti,et al.  Selective Synthesis of Trifluoromethyl β‐Lactams by a Zn‐Promoted 2‐Bromo Ester Addition on C‐CF3‐Substituted Aldimines , 2018 .

[2]  F. Sciubba,et al.  Chiral trans-carboxylic trifluoromethyl 2-imidazolines by a Ag2O-catalyzed Mannich-type reaction , 2017 .

[3]  A. Kirschning,et al.  4-Ethoxy-1,1,1-trifluoro-3-buten-2-one (ETFBO), a Versatile Precursor for Trifluoromethyl-Substituted Heteroarenes – a Short Synthesis of Celebrex® (Celecoxib) , 2017, Synlett.

[4]  F. Ye,et al.  Synthesis and Evaluation of Anti‐inflammatory N‐Substituted 3,5‐Bis(2‐(trifluoromethyl)benzylidene)piperidin‐4‐ones , 2017, ChemMedChem.

[5]  D. Piomelli,et al.  Progress in the development of β-lactams as N-Acylethanolamine Acid Amidase (NAAA) inhibitors: Synthesis and SAR study of new, potent N-O-substituted derivatives. , 2017, European journal of medicinal chemistry.

[6]  S. Fioravanti.  Trifluoromethyl aldimines: an overview in the last ten years , 2016 .

[7]  O. Werz,et al.  Design and Development of Microsomal Prostaglandin E2 Synthase-1 Inhibitors: Challenges and Future Directions. , 2016, Journal of medicinal chemistry.

[8]  S. Hwang,et al.  Potent, orally available, selective COX-2 inhibitors based on 2-imidazoline core. , 2014, European journal of medicinal chemistry.

[9]  N. Mimica-Dukić,et al.  Chemical characterisation and biological effects of Juniperus foetidissima Willd. 1806 , 2013 .

[10]  I. Ojima,et al.  Advances in the chemistry of β-lactam and its medicinal applications. , 2012, Tetrahedron.

[11]  P. Metrangolo,et al.  Organic fluorine compounds: a great opportunity for enhanced materials properties. , 2011, Chemical Society reviews.

[12]  L. Pellacani,et al.  Solvent‐Free Stereoselective Synthesis of (E)‐Trifluoromethyl Imines and Hydrazones. , 2011 .

[13]  D. O'Hagan.  Fluorine in health care: Organofluorine containing blockbuster drugs , 2010 .

[14]  N. Mimica-Dukić,et al.  Liquid chromatography/tandem mass spectrometry study of anti-inflammatory activity of plantain (Plantago L.) species. , 2010, Journal of pharmaceutical and biomedical analysis.

[15]  W. Hagmann,et al.  The many roles for fluorine in medicinal chemistry. , 2008, Journal of medicinal chemistry.

[16]  S. Swallow,et al.  Fluorine in medicinal chemistry. , 2015, Progress in medicinal chemistry.

[17]  B. Crousse,et al.  Barbier Conditions for Reformatsky and Alkylation Reactions on Trifluoromethyl Aldimines , 2008 .

[18]  F. Diederich,et al.  Fluorine in Pharmaceuticals: Looking Beyond Intuition , 2007, Science.

[19]  S. Abramson,et al.  Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. , 2006, Clinical immunology.

[20]  Garret A FitzGerald,et al.  Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. , 2005, The Journal of clinical investigation.

[21]  P. Jeschke.  The Unique Role of Fluorine in the Design of Active Ingredients for Modern Crop Protection , 2004, Chembiochem : a European journal of chemical biology.

[22]  R. G. Hall,et al.  The importance of fluorine in the life science industry , 2004 .

[23]  G. Hatch,et al.  Regulation of cytosolic phospholipase A2, cyclooxygenase-1 and -2 expression by PMA, TNFα, LPS and M-CSF in human monocytes and macrophages , 2003, Molecular and Cellular Biochemistry.

[24]  I. Morita.  Distinct functions of COX-1 and COX-2. , 2002, Prostaglandins & other lipid mediators.

[25]  G. Caughey,et al.  Differential Regulation of Prostaglandin E2 and Thromboxane A2 Production in Human Monocytes: Implications for the Use of Cyclooxygenase Inhibitors1 , 2000, The Journal of Immunology.

[26]  D. Riendeau,et al.  Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells , 1997, Inflammation Research.

[27]  W. Smith,et al.  The eicosanoids and their biochemical mechanisms of action. , 1989, The Biochemical journal.

[28]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.